Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPRS1 | P07814 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.46 |
| ▸ | KCNK10 | P57789 | 2/20 | 0.46 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29451092 | 1.00 | EPRS1 (0.51) | EPRS1KDM4EGLACES2GRIK1 | |
| SCHEMBL27882340 | 0.90 | EPRS1 (0.45) | EPRS1KDM4EGLACES2GRIK1 | |
| SCHEMBL25532291 | 0.86 | CES2 (0.47) | EPRS1KDM4EGLACES2GRIK1 | |
| SCHEMBL30417128 | 0.86 | KDM4E (0.53) | EPRS1KDM4EGLACES2GRIK1 | |
| SCHEMBL158230 | 0.86 | KDM4E (0.53) | EPRS1KDM4EGLACES2GRIK1 | |
| SCHEMBL3143470 | 0.85 | CES2 (0.46) | EPRS1KDM4EGLACES2GRIK1 | |
| SCHEMBL1330833 | 0.85 | DGAT1 (0.59) | EPRS1KDM4EGLACES2HPGD | |
| SCHEMBL29333933 | 0.85 | CES2 (0.46) | EPRS1KDM4EGLACES2GRIK1 | |
| SCHEMBL7787369 | 0.85 | CES2 (0.46) | EPRS1CES2HPGDDGAT1KDM1A | |
| SCHEMBL17159522 | 0.82 | CES2 (0.47) | EPRS1KDM4ECES2GRIK1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079899-A | Application of pharmaceutical composition in preparation of medicines for preventing or treating diseases related to Sirttail 7 protein | — | 2026-05-26 | — | — | CN | disclosed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-20240368122-A1 | JAK2 INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240300944-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-12 | — | — | US | disclosed |
| US-20240226104-A1 | PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-11 | — | — | US | disclosed |
| US-20240226104-A1 | PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-11 | — | — | US | disclosed |
| US-20240226104-A1 | PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-11 | — | — | US | disclosed |
| EP-4387964-A1 | JAK2 INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-114103329-B | Sound-absorbing type automobile carpet assembly and preparation method thereof | 宁波尚唯汽车饰件有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-101151244-A | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2008-03-26 | — | — | CN | disclosed |
| EP-1868991-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | disclosed |
| CN-101048369-A | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1784388-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | AstraZeneca AB (SE) | 2007-05-16 | — | — | EP | disclosed |
| CN-1960969-A | Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof | LILLY CO ELI (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1735278-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006107661-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006021759-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005097740-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368122-A1 | JAK2 INHIBITORS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | EPRS1 816/4885KDM4E 1108/4885GLA 3693/4885 |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | EPRS1 2765/4885KDM4E 435/4885GLA 3442/4885 |
| US-20240226104-A1 | PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF | PI4KA, PIK3CA, PI4KB | EPRS1 4416/4885KDM4E 3154/4885GLA 2568/4885 |
| US-20240300944-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | CDKN1A, RET, UBTF | EPRS1 2173/4885KDM4E 2453/4885GLA 4498/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | EPRS1 497/4885KDM4E 3027/4885GLA 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.